It seems highly likely that over the next 10 years or so MRI will firmly establish itself as imaging tool in Parkinson's disease. In routine clinical practice its main role currently is in helping to diagnose or rule out Parkinson's mimics, such as vascular disease and rarer causes of parkinsonism. I am optimistic that changes such as the ones described in this paper will be useful in making a firm diagnosis of Parkinson's and will also identify people at early stages, before the point of usual diagnosis...
Neurol Sci. 2017 Sep 2. doi: 10.1007/s10072-017-3099-y. [Epub ahead of print]
Pietracupa S, Martin-Bastida A, Piccini P.
https://link.springer.com/article/10.1007%2Fs10072-017-3099-y
Iron deposition in the brain normally increase with age, but its accumulation in certain regions is observed in a number of neurodegenerative diseases including Parkinson's disease (PD) and other parkinsonisms. Whether iron overload leads to dopaminergic neuronal death in the SN of PD patients or is instead simply a by-product of the neurodegenerative progression is still yet to be ascertained. Magnetic resonance imaging (MRI) is a non-invasive method to assess brain iron content in PD patients. In PD, accurate radiologic visualization of basal ganglia is required. Deep gray matter nuclei are well presented in T2- and T2*-weighted images. T2*-weighted gradient-echo (GRE) is widely used to assess calcifications and also for iron detection. On the other hand, new methods specifically designed for detecting iron-induced susceptibility differences can be further improved by sequences like susceptibility-weighted imaging (SWI). In the present review, we aim to summarize the available data on brain iron deposition in PD.
No comments:
Post a Comment